Search PubMed⌕ Search

Biomedical subjects

Y Wakisaka

Publications and source records attributed to Y Wakisaka.

At least 55 records · Page 3Linked to original sources
PubMed1976

Isolation of a new antibiotic, laterosporamine. Studies on antibiotics from the genus Bacillus. XIII.

A new antibiotic, named laterosporamine, was isolated from the culture broth of Bacillus laterosporus 340-19. The antibiotic is active against Gram-positive and Gram-negative bacteria in vitro and in vivo. It is a water-soluble basic substance, positive to ninhydrin, SAKAGUCHI'S and DRAGENDORFF'S reagents. A non-peptidic structure with an approximate empirical formula C17H35N7O4 was suggested.

Animals↗
PubMed1976

Isolation of a new antibiotic 333-25, related to antibiotic EM 49. (Studies on antibiotics from the genus Bacillus. XI).

A new antibiotic, 333-25, active against Gram-positive and Gram-negative bacteria, was isolated from the culture broth of Bacillus circulans 333-25. The antibiotic is a basic acylpeptide containing 2,4-diaminobutyric acid (5), leucine (2), phenylalanine (1) and a fatty acid. It is closely related to antibiotic EM 49, but can be differentiated by chromatographic behaviour.

Animals↗
PubMed1976

New antibiotics, griseusins A and B. Isolation and characterization.

New antibiotics, griseusins A and B were isolated from a strain of Streptomyces griseus. Both antibiotics have a 5-hydroxy-1, 4-naphthoquinone chromophore and their molecular formulae were determined to be C22H20O10 and C22H22O10, respectively. The griseusins are active against gram-positive bacteria.

Animals↗
PubMed1976

Isolation of a new peptide antibiotic complex, B-43 (studies on antibiotics from the genus Bacillus. XV).

A new peptide antibiotic complex B-43, active against Gram-positive and Gram-negative bacteria, was isolated from a strain of Bacillus circulans. This antibiotic contains aspartic acid, valine, isoleucine, leucine, phenylalanine and 2,4-diaminobutyric acid. It seems to be related to polypeptin and antibiotic complex 4205, but differs in that it contains aspartic acid residue.

Animals↗
PubMed1975

Isolation of galantins I and II, water-soluble basic peptides. Studies on antibiotics from the genus Bacillus. III.

Two water-soluble basic antibiotics named galantins I and II were isolated from a strain resembling Bacillus pulvifaciens. Both antibiotics are peptides containing glycine, alanine, ornithine, lysine and some unknown ninhydrin-positive components. An approximate empirical formula C50 plus and minus H98plus and minus 2O17N16 is indicated for galantin I. These are active against some gram-positive, acid-fast and gram-negative bacteria.

Alanine↗
PubMed1975

Isolation of a new peptide antibiotic complex 61-26. Studies on antibiotics from the geneus Bacillus. V.

A new antibiotic named 61-26 active against gram-positive bacteria and some fungi was isolated from a Bacillus strain. The antibiotic is a weakly basic peptide slightly soluble in aqueous alcohols. An approximate empirical formula of C50H93N11O17 and constituent amino acids of aspartic acid (1 mole), serine(2 moles), alanine (2moles), and sum of valine and isoleucine (2 moles) are indicated.

Alanine↗
PubMed1975

Isolation of two new related peptide antibiotics, cerexins A and B (studies on antibiotics from the genus Bacillus. I).

Two new antibiotics cerexins A and B were isolated from different strains identified with Bacillus cereus. These two antibiotics are amphoteric in nature, soluble in particular solvents such as dimethylsulfoxide, dimethylformamide and alkaline water, and show typical infrared absorptions of peptide. These also have similar antimicrobial properties active against gram-postive bacteria.

Animals↗
PubMedDate not supplied

Postoperative chemoimmunotherapy for the treatment of liver cancer.

A randomized study using spleen-derived lymphokine-activated killer (LAK) cells in hepatocellular carcinoma (HCC) is reported. We induced cytotoxic lymphocytes from resected spleen of HCC. The effect of recombinant interleukin-2 (rIL-2)-activated spleen cells for prevention of recurrence of HCC after hepatic resection was studied. Enough mononuclear cells could be harvested from the resected spleens. The induction of activated spleen cells was carried out by culture in fresh medium containing 1,500 JU/ml of IL-2. The cytotoxicity of the activated spleen cells maintained high levels during the culture period ranging from 3-30 days. These autologous activated spleen cells were administered to patients 2 days after the intra-arterial infusion of Adriamycin. A randomized study using these spleen LAK cells resulted in lower recurrence rates in the LAK IL-2-treated group. No severe side effects were observed. The lymphocytes derived from resected spleens were useful as the source of effector cells in clinical adoptive immunochemotherapy for HCC, because of their higher cytotoxicity and the simplicity of gaining a large amount of cells.

Aged↗
PubMedDate not supplied

Development and evaluation of components for a totally implantable artificial heart system.

The authors have been developing an electrohydraulic (EH) artificial heart system for total implantation. This system consists of intrathoracic ventricles, an abdominally placed EH actuator, flexible silicone oil conduits, externally coupled transcutaneous energy transfer (TET) system, transcutaneous optical telemetry (TOT) system, internal battery, and internal control drive unit. Fitting was evaluated in chronic animal experiments as a pneumatic system in 11 goats weighing 55.2 +/- 4.2 kg and 3 calves of 52.3 +/- 1.2 kg. The longest survival time in calves was 111 days, and that in goats was 51 days. The assembled EH pump was implanted in two goats of 49 and 50 kg as an acute experiment, and 4.2-6.7 L/min of cardiac output was maintained. For the TET system, an internal coil 3 cm in diameter was implanted to make an arch covered by skin. Electric energy was transmitted from the external to the internal coil, and energy of about 20 W was carried through wires to an external load. The DC-to-DC efficiency of the system was 76-83% for 40 days. The TOT system with internal light emitting diodes and external photodiodes also was evaluated in a goat. Disalignment of up to 12 mm was tolerated. Although more improvement is necessary, most of the components showed characteristics desirable for a totally implantable system.

Animals↗
PubMedDate not supplied

In vitro and in vivo assessment of an intravenous axial flow pump for right heart assist.

Right ventricular (RV) function is a limiting factor in maintaining systemic circulation with circulatory assist. There is, however, no easy way to institute RV assist, such as the intraarterial axial flow pump (Hemopump) used for left heart assist. In this study, the feasibility and hemodynamic effect of intravenous use of an axial flow pump was examined. A pump system was developed with an outflow cannula and an impeller that were newly designed for intravenous insertion with a Hemopump driving system. The pump system characteristics using goat blood at a hematocrit of 26% indicated that maximum flow at a pressure differential against 40 mmHg is 3.2 l/min at a pump speed of 28,000 rpm. The pump was tested in adult goats by intravenous insertion through a 14 mm, low porosity graft anastomosed to the infrarenal inferior vena cava. The pump was advanced until the tip of the cannula was positioned at the main pulmonary artery, using balloon catheter guidance under fluoroscopy. RV assistance was evaluated by pressure tracing, and aortic flow (AF) measured by electromagnetic flowmeter under 1) induced pulmonary stenosis (PS), and 2) electrically induced ventricular fibrillation (VF) in combination with left heart assist. Under PS, right atrial pressure decreased from 11 to 2 mmHg and AF increased from 1.0 to 4.1 l/min after initiation of the pump. Under VF, AF and aortic pressure were 2.6 l/min and 78 mmHg, respectively, with left ventricular assist. After initiation of the pump, they increased to 4.0 l/min and 98 mmHg, respectively. In chronic experiments using three adults goats for up to 48 hr, levels of plasma hemoglobin and platelet counts were maintained within an acceptable range. There was no prominent damage to the hearts. These data suggest that an axial flow pump introduced by an intravenous approach without thoracotomy is feasible and provides sufficient right heart assist.

Animals↗
PubMedDate not supplied

Heat generation and hemolysis at the shaft seal in centrifugal blood pumps.

The heat and hemolysis around a shaft seal were investigated. Materials were original pumps (Nikkiso HMS-15:N-original, and 3M Delphin:D-original), vane-removed pumps (Nvane(-), Dvane(-)), and a small chamber with a shaft coiled by nichrome wire (mock pump). The original pumps were driven at 500 mmHg and 5 L/min, and vane-removed pumps were driven at the same rotation number. An electrical powers of 0, 0.5, 2, and 10 W was supplied to the mock pumps. In vitro hemolytic testing showed that hemolytic indices were 0.027 g/100 L in N-original, 0.013 in Nvane(-), 0.061 in D-original, and 0.012 in Dvane(-). Measurement of heat with a thermally insulated water chamber showed total heat within the pump of 8.62 and 10.85 W, and heat at the shaft seal of 0.87 and 0.62 W in the Nikkiso and Delphin pumps, respectively. Hemolysis and heat generation of mock pumps remained low. The results indicate that the heat generated around the shaft seal was minimal. Hemolysis at the shaft-seal was considerable but not major. Local heat did not affect hemolysis. It was concluded that the shaft-seal affected hemolysis, not by local heat but friction itself.

Animals↗
PubMedDate not supplied

Development and in vivo evaluation of an implantable left ventricular assist system with an impedance based monitoring and control system.

We have developed an implantable pneumatically driven diaphragm left ventricular assist system (LVAS) for small adults, and an electric impedance based monitoring and control system (Z system). In this Z system, measurement of electric impedance of the blood chamber is performed by charging an alternating current with a constant amplitude between two metal connectors without compromising anti-thrombogenicity. Automatic calibration was performed periodically by measuring trough values of impedance in the blood chamber for several beats while the blood pump was in a full-fill state under preset driving conditions. For precise control of the fill-to-empty (F/E) drive, an automatic trigger level adjustment method was developed. This method is an automatic searching algorithm that identifies the volume change of the last ejection or filling by the Z system and settles the next trigger level to maintain a definite stroke volume. In chronic in vivo evaluation, this LVAS was used in 13 adult goats. The pump was installed between the LV apex and the descending aorta and was placed in the abdominal wall. Pump output ranged from 2.5 to 5.8 L/min, and the Z system provided good monitoring. The F/E drive was achieved satisfactorily by this Z system. The physical condition of the goats was excellent for as long as 19 weeks. Hematologic, hepatic, and renal functions were within the normal range, and no prominent thromboembolic symptoms were observed. A new mobile control drive unit with this Z system is being developed. We conclude that this LVAS with the Z system is promising for long-term use in a clinical setting.

Adult↗
PubMedDate not supplied

Development of an intravenous axial flow pump for temporary right heart assist.

In clinical settings, quick application systems with easy access for circulatory support are desired. For left heart assist, an intraarterial axial flow pump (Hemopump) has been developed and applied to clinical cases. However, no simple way has been proposed for right heart assist. We have developed an intravenous axial flow pump for temporary right heart assist and have reported its hemodynamic effect. In this study, in vivo evaluation of this system was performed. The pump system consists of an outflow cannula, an impeller that was newly developed for intravenous use, and a driving system for the Hemopump. A prototype pump demonstrated 3.2 L/min of maximal flow at a pressure differential against 40 mmHg at a pump speed of 28,000 rpm in mock circulation. Application to goats is as follows. A 14 mm low porosity graft was anastomosed to the infrarenal inferior vena cava (IVC). The pump system was inserted into the IVC through the graft and advanced to the right heart using balloon catheter guidance under fluoroscopy, and the tip of the cannula of the pump was positioned at the main pulmonary artery. In acute experiments, this system provided effective right heart assist under induced pulmonary stenosis and induced biventricular failure with left ventricular assist. Chronic animal experiments were performed for as long as 4 hr using adult goats weighing 51-54 kg. There were no difficulties in pump insertion. In one goat, the drive shaft was broken because of kinking of the shaft inside the body, caused by failure in securing the pump. Levels of platelet counts and plasma hemoglobin were acceptable, and there was no prominent damage to heart tissues. In conclusion, an intravenous axial flow pump introduced through a peripheral vein is practicable for temporary right heart assist.

Animals↗
PubMedDate not supplied

Improvement in antithrombogenicity in a centrifugal pump with self wash-out structure for long-term use.

Antithrombogenicity in the initial (NCVC-1) centrifugal pump (CP) developed at our institute is provided by a central balancing hole in an impeller that promotes self wash-out blood flow (Sf) around the impeller. The current CP (NCVC-2) was ameliorated to obtain better antithrombogenicity, where the balancing hole diameter was widened to improve Sf velocity (Vsf), and the edge of a thrust bearing (TB) was rounded to minimize flow separation. Effects of the modifications were assessed in in vitro and in vivo studies. The Vsf of the NCVC-1 and the NCVC-2 evaluated by Doppler velocimeter were 12.8 and 22.1 cm/sec, respectively. Flow around the TB visualized by a light cutting method confirmed less flow stagnation in the NCVC-2. In vivo antithrombogenicity of the CPs was investigated in three goats. A pulsatile VAD (P-VAD) was installed paracorporeally between the left atrium and the aorta. After 3 weeks, the P-VAD was exchanged for the NCVC-2 and the NCVC-1 in sequence. Each CP was driven for 1 week and disassembled. No anticoagulation was used, except for heparin injection at pump exchange. Thrombus at the TB was found in the two NCVC-1s, and two little thrombi were on the impeller of another NCVC-1, whereas a thrombus smaller than 1 mm3 at the TB was noted in one NCVC-2. These results indicate that the NCVC-2 has better antithrombogenicity and Sf around the impeller and the TB.

Animals↗